Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
- Author
- ERON, Joseph J1 ; YOUNG, Benjamin2 ; KUMAR, Princy N11 ; RODGERS, Anthony J12 ; SHAUGHNESSY, Melissa A12 ; WALKER, Monica L12 ; BARNARD, Richard Jo12 ; MILLER, Michael D12 ; DINUBILE, Mark J12 ; NGUYEN, Bach-Yen12 ; LEAVITT, Randi12 ; XIA XU12 ; COOPER, David A3 ; SKLAR, Peter12 ; YOULE, Michael4 ; DEJESUS, Edwin5 ; ANDRADE-VILLANUEVA, Jaime6 ; WORKMAN, Cassy7 ; ZAJDENVERG, Roberto8 ; FÄTKENHEUER, Gerd9 ; BERGER, Daniel S10
[1] University of North Carolina School of Medicine, Chapel Hill, NC, United States
[2] Denver Infectious Disease Consultants, Denver, CO, United States
[3] National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
[4] Garrett Anderson Ward Royal Free Hospital, London, United Kingdom
[5] Orlando Immunology Center, Orlando, FL, United States
[6] Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico
[7] AIDS Research Initiative, Darlinghurst, NSW, Australia
[8] Projeto Praça Onze, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
[9] Department of Internal Medicine, University of Cologne, Cologne, Germany
[10] Northstar Medical Center, University of Illinois at Chicago, Chicago, IL, United States
[11] Georgetown University Medical Center, Washington, DC, United States
[12] Merck Research Laboratories, North Wales, PA, United States
SWITCHMRK 1 and 2 investigators - Source
Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, 12 p ; ref : 36 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antirétroviral Antiviral Essai clinique Etude comparative Etude double insu Etude multicentrique Lopinavir Médecine Protocole thérapeutique Raltégravir Ritonavir SIDA Virémie Essai randomisé contrôlé Inhibiteur de transfert de brins Enzyme Hydrolases Immunodéficit Immunopathologie Infection Inhibiteur de l'intégrase Inhibiteur enzyme Inhibiteur protease Peptidases Virose
- Keyword (en)
- Antiretroviral agent Antiviral Clinical trial Comparative study Double blind study Multicenter study Lopinavir Medicine Therapeutic protocol Raltegravir Ritonavir AIDS Viremia Randomized controlled trial Enzyme Hydrolases Immune deficiency Immunopathology Infection Integrase inhibitor Enzyme inhibitor Protease inhibitor Peptidases Viral disease
- Keyword (es)
- Antiretroviral Antiviral Ensayo clínico Estudio comparativo Estudio doble ciego Estudio multicéntrico Lopinavir Medicina Protocolo terapéutico Raltegravir Ritonavir SIDA Viremia Ensayo aleatorio controlado Enzima Hydrolases Inmunodeficiencia Inmunopatología Infección Inhibidor integrase Inhibidor enzima Inhibidor proteasa Peptidases Virosis
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Discipline
- Generalities in medical sciences Infectious pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 22351365
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(09)62041-9 
https://dx.doi.org/10.1016/S0140-6736(09)62041-9
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(09)62041-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9712\";s:8:\"\u0000*\u0000spage\";s:3:\"396\";s:8:\"\u0000*\u0000epage\";s:3:\"407\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"YOUNG, Benjamin\";i:1;s:15:\"KUMAR, Princy N\";i:2;s:18:\"RODGERS, Anthony J\";i:3;s:22:\"SHAUGHNESSY, Melissa A\";i:4;s:16:\"WALKER, Monica L\";i:5;s:19:\"BARNARD, Richard Jo\";i:6;s:17:\"MILLER, Michael D\";i:7;s:16:\"DINUBILE, Mark J\";i:8;s:16:\"NGUYEN, Bach-Yen\";i:9;s:14:\"LEAVITT, Randi\";i:10;s:6:\"XIA XU\";i:11;s:15:\"COOPER, David A\";i:12;s:12:\"SKLAR, Peter\";i:13;s:14:\"YOULE, Michael\";i:14;s:14:\"DEJESUS, Edwin\";i:15;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:16;s:14:\"WORKMAN, Cassy\";i:17;s:19:\"ZAJDENVERG, Roberto\";i:18;s:18:\"F\u00c4TKENHEUER, Gerd\";i:19;s:16:\"BERGER, Daniel S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(09)62041-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9712\";s:8:\"\u0000*\u0000spage\";s:3:\"396\";s:8:\"\u0000*\u0000epage\";s:3:\"407\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"YOUNG, Benjamin\";i:1;s:15:\"KUMAR, Princy N\";i:2;s:18:\"RODGERS, Anthony J\";i:3;s:22:\"SHAUGHNESSY, Melissa A\";i:4;s:16:\"WALKER, Monica L\";i:5;s:19:\"BARNARD, Richard Jo\";i:6;s:17:\"MILLER, Michael D\";i:7;s:16:\"DINUBILE, Mark J\";i:8;s:16:\"NGUYEN, Bach-Yen\";i:9;s:14:\"LEAVITT, Randi\";i:10;s:6:\"XIA XU\";i:11;s:15:\"COOPER, David A\";i:12;s:12:\"SKLAR, Peter\";i:13;s:14:\"YOULE, Michael\";i:14;s:14:\"DEJESUS, Edwin\";i:15;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:16;s:14:\"WORKMAN, Cassy\";i:17;s:19:\"ZAJDENVERG, Roberto\";i:18;s:18:\"F\u00c4TKENHEUER, Gerd\";i:19;s:16:\"BERGER, Daniel S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(09)62041-9\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(09)62041-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9712\";s:8:\"\u0000*\u0000spage\";s:3:\"396\";s:8:\"\u0000*\u0000epage\";s:3:\"407\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"YOUNG, Benjamin\";i:1;s:15:\"KUMAR, Princy N\";i:2;s:18:\"RODGERS, Anthony J\";i:3;s:22:\"SHAUGHNESSY, Melissa A\";i:4;s:16:\"WALKER, Monica L\";i:5;s:19:\"BARNARD, Richard Jo\";i:6;s:17:\"MILLER, Michael D\";i:7;s:16:\"DINUBILE, Mark J\";i:8;s:16:\"NGUYEN, Bach-Yen\";i:9;s:14:\"LEAVITT, Randi\";i:10;s:6:\"XIA XU\";i:11;s:15:\"COOPER, David A\";i:12;s:12:\"SKLAR, Peter\";i:13;s:14:\"YOULE, Michael\";i:14;s:14:\"DEJESUS, Edwin\";i:15;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:16;s:14:\"WORKMAN, Cassy\";i:17;s:19:\"ZAJDENVERG, Roberto\";i:18;s:18:\"F\u00c4TKENHEUER, Gerd\";i:19;s:16:\"BERGER, Daniel S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(09)62041-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9712\";s:8:\"\u0000*\u0000spage\";s:3:\"396\";s:8:\"\u0000*\u0000epage\";s:3:\"407\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"YOUNG, Benjamin\";i:1;s:15:\"KUMAR, Princy N\";i:2;s:18:\"RODGERS, Anthony J\";i:3;s:22:\"SHAUGHNESSY, Melissa A\";i:4;s:16:\"WALKER, Monica L\";i:5;s:19:\"BARNARD, Richard Jo\";i:6;s:17:\"MILLER, Michael D\";i:7;s:16:\"DINUBILE, Mark J\";i:8;s:16:\"NGUYEN, Bach-Yen\";i:9;s:14:\"LEAVITT, Randi\";i:10;s:6:\"XIA XU\";i:11;s:15:\"COOPER, David A\";i:12;s:12:\"SKLAR, Peter\";i:13;s:14:\"YOULE, Michael\";i:14;s:14:\"DEJESUS, Edwin\";i:15;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:16;s:14:\"WORKMAN, Cassy\";i:17;s:19:\"ZAJDENVERG, Roberto\";i:18;s:18:\"F\u00c4TKENHEUER, Gerd\";i:19;s:16:\"BERGER, Daniel S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(09)62041-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"375\";s:8:\"\u0000*\u0000issue\";s:4:\"9712\";s:8:\"\u0000*\u0000spage\";s:3:\"396\";s:8:\"\u0000*\u0000epage\";s:3:\"407\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"YOUNG, Benjamin\";i:1;s:15:\"KUMAR, Princy N\";i:2;s:18:\"RODGERS, Anthony J\";i:3;s:22:\"SHAUGHNESSY, Melissa A\";i:4;s:16:\"WALKER, Monica L\";i:5;s:19:\"BARNARD, Richard Jo\";i:6;s:17:\"MILLER, Michael D\";i:7;s:16:\"DINUBILE, Mark J\";i:8;s:16:\"NGUYEN, Bach-Yen\";i:9;s:14:\"LEAVITT, Randi\";i:10;s:6:\"XIA XU\";i:11;s:15:\"COOPER, David A\";i:12;s:12:\"SKLAR, Peter\";i:13;s:14:\"YOULE, Michael\";i:14;s:14:\"DEJESUS, Edwin\";i:15;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:16;s:14:\"WORKMAN, Cassy\";i:17;s:19:\"ZAJDENVERG, Roberto\";i:18;s:18:\"F\u00c4TKENHEUER, Gerd\";i:19;s:16:\"BERGER, Daniel S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:234:\"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
